This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pharmspective Launches Affordable Care Act Knowledge And News Hub For Healthcare Decision-Makers

NEW YORK, Nov. 27, 2012 /PRNewswire/ -- Pharmspective, LLC announced the launch today of HealthcareReformInsider.com, a knowledge and news hub for key stakeholders impacted by the Affordable Care Act (ACA).  HealthcareReformInsider.com will aggregate news, research, policy analysis, and government directives on the ACA for key decision makers assessing upcoming strategic choices driven by implementation of the ACA.   Pharmspective provide market research and knowledge management applications to the pharmaceutical industry.

"We set out to simplify the acquisition of Healthcare Reform information for key decision makers when we designed HealthcareReformInsider.com," stated Katie Derdeyn, M.D., Managing Partner & Co-Founder of Pharmspective.  "There is a real need for an information portal that vets everything that's written about the ACA and extracts what's relevant for building strategies for leading healthcare organizations. HealthcareReformInsider.com will do that and ensure that its users are up-to-date on the latest key developments involving the Affordable Care Act."

By honing in on the emerging and evolving insurer entities (State Exchanges, Medicaid, and Medicare) that will drive expansion of coverage, the new healthcare models that will drive changes in how care is provided (ACOs, Community Health Centers, Medical Homes, etc.), and the regulations that will influence payment (MLR rules, Individual Mandate, Quality-based Incentives, etc.), HealthcareReformInsider.com provides a destination for knowledge acquisition related to this expansive legislation.

"Our experience in helping healthcare organizations understand the ACA has allowed us to construct a site that provides the most relevant and current ACA news and policy analysis," said Stephen Reid, Managing Partner and leader of Pharmspective's Healthcare Reform practice.  "Following HealthcareReformInsider.com on the web and on Twitter (@hcrinsider) will keep healthcare decision-makers informed on the latest ACA developments that impact their market strategies."

About Pharmspective: Pharmspective, LLC (pharmspective.com) is a Specialty Therapeutics Market Research firm providing commercial insights and knowledge management applications for the biopharmaceutical industry. The company is uniquely focused on understanding the buying process for specialty therapeutics through syndicated market research studies examining clinical decision-making, drug acquisition, access and reimbursement, and therapy administration for specialty therapeutics in autoimmune diseases and Oncology. Pharmspective's Healthcare Reform team provides insights into the Affordable Care Act through its proprietary ClearView knowledge management application, market assessments of the impact of key ACA provisions on healthcare decision-makers, and its HealthCareReformInsider.com website. The company maintains offices in New York City and St. Louis, MO.  Follow Pharmspective on Twitter at twitter.com/Pharmspective and follow HealthcareReformInsider.com on Twitter at twitter.com/hcrinsider.

Contact: Cindy Wong Tel: 314-814-2729 x1003 cindy.wong@Pharmspective.com.

SOURCE Pharmspective, LLC

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs